Kiora Pharmaceuticals Announces Publication of Phase 1 Trial Results for KIO-100 as a Treatment for Ocular Inflammatory DiseaseNewsfile Corp • 10/17/22
Battling Blindness: Virtual Investor Event on Treatments for Retinitis Pigmentosa to Be Held October 19; Panelists include Kiora Pharmaceuticals, Foundation Fighting Blindness, and Retinal Surgeon Christine Kay, M.D.Newsfile Corp • 09/28/22
Kiora Pharmaceuticals Appoints Melissa Tosca as Executive Vice President of FinanceNewsfile Corp • 09/13/22
Kiora Pharmaceuticals Reports First Half 2022 Business Update and Financial ResultsNewsfile Corp • 08/12/22
Kiora Pharmaceuticals Issued US Patent Covering KIO-201 Technology in Combination with AntibioticsNewsfile Corp • 07/28/22
Kiora Pharmaceuticals Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Over-Allotment OptionNewsfile Corp • 07/26/22
Kiora Pharmaceuticals Announces Pricing of $5.2 Million Underwritten Public OfferingNewsfile Corp • 07/22/22
Kiora Pharmaceuticals Announces First Patient Enrolled in Phase 2 Study Evaluating KIO-201 for Persistent Corneal Epithelial DefectsNewsfile Corp • 07/05/22
Kiora Pharmaceuticals Receives Clinical Trial Approval for First-in-Human Evaluation of KIO-301 to Restore Vision in Patients with Retinitis PigmentosaNewsfile Corp • 06/27/22
Kiora Pharmaceuticals Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)Newsfile Corp • 05/31/22
Kiora Pharmaceuticals Announces Presentation of KIO-101 Clinical Trial Data at the American Society of Cataract and Refractive Surgery 2022Newsfile Corp • 04/25/22
Kiora Pharmaceuticals to Participate in Maxim Group's 2022 Virtual Growth Conference March 28th - 30thNewsfile Corp • 03/21/22
Kiora Pharmaceuticals Granted Orphan Drug Designation for KIO-301, an Investigational Drug for the Treatment of Retinitis Pigmentosa (RP)Newsfile Corp • 03/18/22
Kiora Pharmaceuticals Announces Participation at 2022 BIO CEO & Investor ConferenceNewsfile Corp • 02/08/22
Kiora Pharmaceuticals Appoints Erin Parsons to its Board of Directors; Stephen From to Retire from BoardNewsfile Corp • 02/01/22